Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noncytotoxic drug therapy versus capecitabine versus combined therapy after D2 radical gastrectomy for gastric carcinoma
ChiCTR-TNRC-08000052Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2008
- Modality
- Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of celecoxib, lanreotide and capecitabine in gastric adenocarcinoma (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Annual survival rate and 5-year survival rate, Regional and systemic recurrence rate and recurrence time and 1 more. Started Feb 2008; status: recruiting.
02
Drugs
celecoxiblanreotidecapecitabine
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-TNRC-08000052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNRC-08000052.